Particle.news
Download on the App Store
14 ARTICLES
·
2w ago

Roche Announces $50 Billion U.S. Expansion in Response to Tariff Threats

The investment will create over 12,000 jobs, expand manufacturing and R&D facilities across multiple states, and shift the company to a U.S. export surplus.

Roche is attempting to placate Trump in his trade vendetta.
Signage for Roche Holding AG on a building in the company's headquarters campus in Basel, Switzerland, on Monday, Jan. 8, 2023. Swiss pharma giants Roche and Novartis AG embody opposing approaches to solving a fundamental puzzle: how to placate shareholders and keep growing in an industry where the hunt for the next blockbuster drug is paramount. Photographer: Stefan Wermuth/Bloomberg
BASEL, SWITZERLAND - APRIL 11: A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Before US President Donald Trump postponed a range of imminent tariffs, Switzerland was facing a daunting 31% levy on most Swiss goods to imported to the United States, a higher rate than would have been imposed on European Union countries. Such a tariff would've been high damaging to iconic Swiss industries like chocolate and watchmaking. The reprieve will provide breathing room for Swiss officials looking to negotiate a deal with the US, although Swiss goods will still face a 10% tariff in the meantime, and the fate of a potential separate tariff on pharmaceuticals is unknown. (Photo by Sedat Suna/Getty Images)
Image

Overview

  • Roche plans to invest $50 billion over five years to expand its U.S. manufacturing and R&D footprint, creating over 12,000 jobs.
  • New facilities will be built in Indiana, Pennsylvania, Massachusetts, and California, with a focus on AI research and next-generation medicines like weight-loss drugs and gene therapy.
  • A 900,000 sq ft manufacturing center for weight-loss medicines is planned, though the location has not yet been disclosed.
  • Roche has committed to exporting more medicines from the U.S. than it imports once the expanded facilities become operational.
  • The announcement follows President Trump's threats to impose tariffs on pharmaceutical imports, prompting major investments by global drugmakers.